1,295 results on '"Thursz, Mark"'
Search Results
2. Phenogrouping heart failure with preserved or mildly reduced ejection fraction using electronic health record data
3. All‐cause and liver‐related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank
4. Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide:diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity
5. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis
6. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers
7. IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab
8. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis
9. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes
10. The role of neutrophils in alcohol-related hepatitis
11. Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease
12. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study
13. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study
14. Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder
15. Rapid Point-of-Care Test for Hepatitis B Core-Related Antigen to Diagnose High Viral Load in Resource-Limited Settings
16. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits
17. FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease
18. FRI-431 The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia
19. FRI-286 Muscle function and walking time are associated with better quality of life in MASLD patients
20. THU-247-YI Multi-tissue profiling of oxylipins reveal a conserved upregulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity
21. LBO-003 Results of a phase 2b multicenter randomized trial of larsucosterol for the treatment of severe alcohol-associated hepatitis (AHFIRM trial)
22. OS-008-YI Cellular senescence is reduced following alcohol cessation in severe alcohol-associated hepatitis
23. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression
24. WED-546 Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males
25. SAT-274 Serum proteomic analyses reveal elevated HGFand IL-8 in patients with alcohol-related hepatitis compared to decompensated alcohol-related cirrhosis and can differentiate patients with AH at risk of infection from those at risk of acute kidney injury
26. THU-326 Improvement in alcohol-associated hepatitis is characterized by reduction of RNA modification processes
27. WED-075-YI Exploring the immunomodulatory potential of TLR7/8 agonism in decompensated cirrhosis
28. Healthcare interactions prior to first hospital admission with alcohol‐related liver disease
29. Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?
30. HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme
31. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania
32. Association of troponin level and age with mortality in 250 000 patients : cohort study across five UK acute care centres
33. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis/Progres accomplis dans l'elimination de la transmission de l'infection au virus de l'hepatite B de la mere a l'enfant en Chine: analyse par modelisation/Avances en la eliminacion de la transmision maternofilial de la infeccion por el virus de la hepatitis B en China: un analisis de modelos
34. Hepatitis B virus preS2Δ38–55 variants: A newly identified risk factor for hepatocellular carcinoma
35. Global hepatitis C elimination: an investment framework
36. High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
37. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England
38. Treatment of Severe Alcoholic Hepatitis
39. Editorial: Unmasking the silent threat—acute kidney injury in alcohol‐associated hepatitis. Authors' reply
40. In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs
41. Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study
42. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases
43. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial
44. Immune-based therapies for hepatocellular carcinoma
45. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study
46. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
47. Endpoints and patient stratification in clinical trials for alcoholic hepatitis
48. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota
49. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa
50. A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.